Label: DIPYRIDAMOLE- dipyridamole tablet 

  • NDC Code(s): 0115-1070-01, 0115-1070-03, 0115-1071-01, 0115-1071-03, view more
    0115-1072-01, 0115-1072-03
  • Packager: Global Pharmaceuticals, Division of Impax Laboratories Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated 11/13

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Rx only

    PRESCRIBING INFORMATION

    Close
  • DESCRIPTION

    Dipyridamole tablets are a platelet inhibitor chemically described as 2,2',2",2'''-[(4,8-Dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]-tetraethanol. The molecular weight is 504.63 and the molecular formula is C24H40N8O4. The structural formula is represented below:

    Chemical Structure

    Dipyridamole is an odorless yellow crystalline powder, having a bitter taste. It is soluble in dilute acids, methanol and chloroform, and practically insoluble in water.

    Each tablet, for oral administration, contains 25 mg, 50 mg or 75 mg dipyridamole. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, povidone, pregelatinized starch, sodium starch glycolate, talc, and titanium dioxide.

    Close
  • CLINICAL PHARMACOLOGY

    It is believed that platelet reactivity and interaction with prosthetic cardiac valve surfaces, resulting in abnormally shortened platelet survival time, is a significant factor in thromboembolic complications occurring in connection with prosthetic heart valve replacement.

    Dipyridamole tablets have been found to lengthen abnormally shortened platelet survival time in a dose-dependent manner.

    In three randomized controlled clinical trials involving 854 patients who had undergone surgical placement of a prosthetic heart valve, dipyridamole tablets, in combination with warfarin, decreased the incidence of postoperative thromboembolic events by 62 to 91% compared to warfarin treatment alone. The incidence of thromboembolic events in patients receiving the combination of dipyridamole tablets and warfarin ranged from 1.2 to 1.8%.

    In three additional studies involving 392 patients taking dipyridamole tablets and coumarin-like anticoagulants, the incidence of thromboembolic events ranged from 2.3 to 6.9%.

    In these trials, the coumarin anticoagulant was begun between 24 hours and 4 days postoperatively, and the dipyridamole tablets were begun between 24 hours and 10 days postoperatively. The length of follow-up in these trials varied from 1 to 2 years.

    Dipyridamole tablets do not influence prothrombin time or activity measurements when administered with warfarin.

    Mechanism of Action

    Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo; the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5 to 1.9 µg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A2-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3',5'-adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP).

    Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. While the inhibition of cAMP-PDE is weak, therapeutic levels of dipyridamole inhibit cyclic-3',5'-guanosine monophosphate-PDE (cGMP-PDE), thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing factor, now identified as nitric oxide).

    Hemodynamics

    In dogs intraduodenal doses of dipyridamole of 0.5 to 4.0 mg/kg produced dose-related decreases in systemic and coronary vascular resistance leading to decreases in systemic blood pressure and increases in coronary blood flow. Onset of action was in about 24 minutes and effects persisted for about 3 hours.

    Similar effects were observed following IV dipyridamole in doses ranging from 0.025 to 2.0 mg/kg.

    In man the same qualitative hemodynamic effects have been observed. However, acute intravenous administration of dipyridamole may worsen regional myocardial perfusion distal to partial occlusion of coronary arteries.

    Pharmacokinetics and Metabolism

    Following an oral dose of dipyridamole tablets, the average time to peak concentration is about 75 minutes. The decline in plasma concentration following a dose of dipyridamole tablets fits a two-compartment model. The alpha half-life (the initial decline following peak concentration) is approximately 40 minutes. The beta half-life (the terminal decline in plasma concentration) is approximately 10 hours. Dipyridamole is highly bound to plasma proteins. It is metabolized in the liver where it is conjugated as a glucuronide and excreted with the bile.

    Close
  • INDICATIONS AND USAGE

    Dipyridamole tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.

    Close
  • CONTRAINDICATIONS

    Hypersensitivity to dipyridamole and any of the other components.

    Close
  • PRECAUTIONS

    General

    Coronary Artery Disease

    Dipyridamole has a vasodilatory effect and should be used with caution in patients with severe coronary artery disease (e.g., unstable angina or recently sustained myocardial infarction). Chest pain may be aggravated in patients with underlying coronary artery disease who are receiving dipyridamole.

    Hepatic Insufficiency

    Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole administration.

    Hypotension

    Dipyridamole should be used with caution in patients with hypotension since it can produce peripheral vasodilation.

    Laboratory Tests

    Dipyridamole has been associated with elevated hepatic enzymes.

    Drug Interactions

    No pharmacokinetic drug-drug interaction studies were conducted with dipyridamole tablets. The following information was obtained from the literature.

    Adenosine

    Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary.

    Cholinesterase Inhibitors

    Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    In studies in which dipyridamole was administered in the feed to mice (up to 111 weeks in males and females) and rats (up to 128 weeks in males and up to 142 weeks in females), there was no evidence of drug-related carcinogenesis. The highest dose administered in these studies (75 mg/kg/day) was, on a mg/m2 basis, about equivalent to the maximum recommended daily human oral dose (MRHD) in mice and about twice the MRHD in rats. Mutagenicity tests of dipyridamole with bacterial and mammalian cell systems were negative. There was no evidence of impaired fertility when dipyridamole was administered to male and female rats at oral doses up to 500 mg/kg/day (about 12 times the MRHD on a mg/m2 basis). A significant reduction in number of corpora lutea with consequent reduction in implantations and live fetuses was, however, observed at 1250 mg/kg (more than 30 times the MRHD on a mg/m2 basis).

    Pregnancy

    Teratogenic Effects

    PREGNANCY CATEGORY B

    Reproduction studies have been performed in mice, rabbits and rats at oral dipyridamole doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1 ½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m2 basis) and have revealed no evidence of harm to the fetus due to dipyridamole. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, dipyridamole tablets should be used during pregnancy only if clearly needed.

    Nursing Mothers

    As dipyridamole is excreted in human milk, caution should be exercised when dipyridamole tablets are administered to a nursing woman.

    Pediatric Use

    Safety and effectiveness in the pediatric population below the age of 12 years have not been established.

    Close
  • ADVERSE REACTIONS

    Adverse reactions at therapeutic doses are usually minimal and transient. On long-term use of dipyridamole tablets initial side effects usually disappear. The following reactions in Table 1 were reported in two heart valve replacement trials comparing dipyridamole tablets and warfarin therapy to either warfarin alone or warfarin and placebo:

    Table 1 Adverse Reactions Reported in 2 Heart Valve Replacement Trials
    Adverse Reaction Dipyridamole Tablets/Warfarin Placebo/Warfarin
    Number of patients 147 170
    Dizziness 13.6% 8.2%
    Abdominal distress 6.1% 3.5%
    Headache 2.3% 0.0%
    Rash 2.3% 1.1%

    Other reactions from uncontrolled studies include diarrhea, vomiting, flushing and pruritus. In addition, angina pectoris has been reported rarely and there have been rare reports of liver dysfunction. On those uncommon occasions when adverse reactions have been persistent or intolerable, they have ceased on withdrawal of the medication.

    When dipyridamole tablets were administered concomitantly with warfarin, bleeding was no greater in frequency or severity than that observed when warfarin was administered alone. In rare cases, increased bleeding during or after surgery has been observed.

    In post-marketing reporting experience, there have been rare reports of hypersensitivity reactions (such as rash, urticaria, severe bronchospasm, and angioedema), larynx edema, fatigue, malaise, myalgia, arthritis, nausea, dyspepsia, paresthesia, hepatitis, thrombocytopenia, alopecia, cholelithiasis, hypotension, palpitation, and tachycardia.

    Close
  • OVERDOSAGE

    In case of real or suspected overdose, seek medical attention or contact a Poison Control Center immediately. Careful medical management is essential. Based upon the known hemodynamic effects of dipyridamole, symptoms such as warm feeling, flushes, sweating, restlessness, feeling of weakness and dizziness may occur. A drop in blood pressure and tachycardia might also be observed.

    Symptomatic treatment is recommended, possibly including a vasopressor drug. Gastric lavage should be considered. Administration of xanthine derivatives (e.g., aminophylline) may reverse the hemodynamic effects of dipyridamole overdose. Since dipyridamole is highly protein bound, dialysis is not likely to be of benefit.

    Close
  • DOSAGE AND ADMINISTRATION

    Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement

    The recommended dose is 75 to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.

    Close
  • HOW SUPPLIED

    Dipyridamole Tablets USP, 25 mg are white to pale yellow, round, standard convex film-coated tablets debossed with "C81" on one side and plain on the other side.

    Bottles of 100 NDC 0115-1070-01
    Bottles of 1000 NDC 0115-1070-03

    Dipyridamole Tablets USP, 50 mg are white to pale yellow, round, standard convex film-coated tablets debossed with "C82" on one side and plain on the other side.

    Bottles of 100 NDC 0115-1071-01
    Bottles of 1000 NDC 0115-1071-03

    Dipyridamole Tablets USP, 75 mg are white to pale yellow, round, standard convex film-coated tablets debossed with "C83" on one side and plain on the other side.

    Bottles of 100 NDC 0115-1072-01
    Bottles of 1000 NDC 0115-1072-03

    Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].

    Dispense in a tightly-closed, light-resistant container (USP). Keep out of reach of children.

    Close
  • SPL UNCLASSIFIED SECTION

    Rx only

    Dist. By:
    Global Pharmaceuticals
    Division of IMPAX Laboratories, Inc.
    Philadelphia, PA 19124 USA

    657-02
    Rev. 07/2013

    Close
  • PRINCIPAL DISPLAY PANEL - 25 mg Tablet Label

    GLOBAL®

    NDC 0115-1070-01

    Dipyridamole
    Tablets, USP

    25 mg

    Rx only

    100 Tablets

    PRINCIPAL DISPLAY PANEL - 25 mg Tablet Label
    Close
  • PRINCIPAL DISPLAY PANEL - 50 mg Tablet Label

    GLOBAL®

    NDC 0115-1071-01

    Dipyridamole
    Tablets, USP

    50 mg

    Rx only

    100 Tablets

    PRINCIPAL DISPLAY PANEL - 50 mg Tablet Label
    Close
  • PRINCIPAL DISPLAY PANEL - 75 mg Tablet Label

    GLOBAL®

    NDC 0115-1072-01

    Dipyridamole
    Tablets, USP

    75 mg

    Rx only

    100 Tablets

    PRINCIPAL DISPLAY PANEL - 75 mg Tablet Label
    Close
  • INGREDIENTS AND APPEARANCE
    DIPYRIDAMOLE 
    dipyridamole tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0115-1070
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    DIPYRIDAMOLE (DIPYRIDAMOLE) DIPYRIDAMOLE 25 mg
    Inactive Ingredients
    Ingredient Name Strength
    STARCH, CORN  
    HYPROMELLOSES  
    MAGNESIUM STEARATE  
    LACTOSE MONOHYDRATE  
    POVIDONES  
    SODIUM STARCH GLYCOLATE TYPE A POTATO  
    POLYETHYLENE GLYCOLS  
    TALC  
    TITANIUM DIOXIDE  
    SILICON DIOXIDE  
    Product Characteristics
    Color WHITE Score no score
    Shape ROUND Size 6mm
    Flavor Imprint Code C81
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0115-1070-01 100 in 1 BOTTLE
    2 NDC:0115-1070-03 1000 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA040782 07/18/2007
    DIPYRIDAMOLE 
    dipyridamole tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0115-1071
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    DIPYRIDAMOLE (DIPYRIDAMOLE) DIPYRIDAMOLE 50 mg
    Inactive Ingredients
    Ingredient Name Strength
    STARCH, CORN  
    HYPROMELLOSES  
    MAGNESIUM STEARATE  
    LACTOSE MONOHYDRATE  
    POVIDONES  
    SODIUM STARCH GLYCOLATE TYPE A POTATO  
    POLYETHYLENE GLYCOLS  
    TALC  
    TITANIUM DIOXIDE  
    SILICON DIOXIDE  
    Product Characteristics
    Color WHITE Score no score
    Shape ROUND Size 6mm
    Flavor Imprint Code C82
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0115-1071-01 100 in 1 BOTTLE
    2 NDC:0115-1071-03 1000 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA040782 07/18/2007
    DIPYRIDAMOLE 
    dipyridamole tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0115-1072
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    DIPYRIDAMOLE (DIPYRIDAMOLE) DIPYRIDAMOLE 75 mg
    Inactive Ingredients
    Ingredient Name Strength
    STARCH, CORN  
    HYPROMELLOSES  
    MAGNESIUM STEARATE  
    LACTOSE MONOHYDRATE  
    POVIDONES  
    SODIUM STARCH GLYCOLATE TYPE A POTATO  
    POLYETHYLENE GLYCOLS  
    TALC  
    TITANIUM DIOXIDE  
    SILICON DIOXIDE  
    Product Characteristics
    Color WHITE Score no score
    Shape ROUND Size 6mm
    Flavor Imprint Code C83
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0115-1072-01 100 in 1 BOTTLE
    2 NDC:0115-1072-03 1000 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA040782 07/18/2007
    Labeler - Global Pharmaceuticals, Division of Impax Laboratories Inc. (116732830)
    Establishment
    Name Address ID/FEI Business Operations
    Impax Laboratories Inc 790947167 MANUFACTURE(0115-1070, 0115-1071, 0115-1072)
    Establishment
    Name Address ID/FEI Business Operations
    Global Pharmaceuticals, Division of Impax Laboratories Inc. 116732830 REPACK(0115-1070, 0115-1071, 0115-1072)
    Close